The U.S. FDA approved Pfizer’s ABRYSVO (respiratory syncytial virus vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant women at 32 through 36 weeks gestational age. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains. The FDA’s decision is based on data from the Phase 3 clinic...